GT Biopharma, Inc. (GTBP) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by GT Biopharma, Inc. on November 20, 2025. The Company is incorporated in Delaware and its common stock trades on The Nasdaq Capital Market under the symbol "GTBP". As of July 1, 2024, the Company operates as a fully remote entity without a principal executive office.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on regulatory compliance regarding stock listing standards.
Material Changes and Listing Status
On November 20, 2025, the Company received a notice from the Nasdaq Listing Qualifications Staff indicating non-compliance with the $1.00 minimum bid price requirement (Nasdaq Listing Rule 5550(a)(2)). This deficiency occurred because the Common Stock closed below $1.00 per share for 30 consecutive business days. The stock continues to trade on Nasdaq pending compliance.
Outlook, Risks, and Contingencies
- Compliance Period: The Company has been granted an initial 180-calendar day compliance period, ending May 19, 2026, to regain compliance.
- Regaining Compliance: Compliance is achieved if the closing bid price is at least $1.00 per share for 10 consecutive business days during the compliance period.
- Secondary Options: If the initial period expires without compliance, the Company may be eligible for an additional 180-day period if it meets market value requirements and notifies Nasdaq of its intent to cure the deficiency, potentially via a reverse stock split.
- Delisting Risk: If the Company fails to regain compliance within the allotted periods, its stock will be subject to delisting. Management stated there can be no assurance that compliance will be achieved.
Key Facts for Investor Verification
- Verify the current trading price of GTBP to assess the likelihood of meeting the $1.00 threshold within the 180-day window.
- Monitor for any announcements regarding a reverse stock split as a potential cure mechanism.
- Review the Company's cash position and capitalization to evaluate its ability to sustain operations if delisting occurs.
- Check for any subsequent filings regarding the status of the compliance period or extensions.